Potential Med Errors Prompt FDA Action on Vinca Alkaloid Labeling
Chemotherapy agents such as vincristine sulfate injection, vinblastine sulfate injection, and vinorelbine tartrate injection should only be prepared in IV infusion bags.
Prostate And Other Male Cancers
Overall Survival Data Added to Nubeqa Prescribing Information
Nubeqa, an androgen receptor inhibitor, was approved for the treatment of patients with nmCRPC based on data from the placebo-controlled phase 3 ARAMIS trial.
Orgovyx Now Available for Advanced Prostate Cancer
Orgovyx is an oral nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist.
New Drugs Approved in 2020
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Orgovyx Approved for Advanced Prostate Cancer
Orgovyx is an oral nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist.
Gallium 68 PSMA-11 Approved for Prostate Cancer Detection
The approval was based on efficacy and safety data from 2 prospective clinical trials.
Guidance Issued for Genetic Testing in Prostate Cancer
Germline testing advised for metastatic disease, family history suggestive of hereditary disease
Spironolactone Use Associated With Reduced Prostate Cancer Risk
Men who had ever used spironolactone had decreased odds of prostate cancer compared with never-users, according to a study.
New Guideline Issued for Managing Advanced Prostate Cancer
Three major medical organizations have issued recommendations for the diagnosis and treatment of advanced prostate cancer, including metastatic hormone-sensitive disease and nonmetastatic and metastatic castration-resistant disease.
ASCO: Relugolix Superior to Leuprolide in Advanced Prostate Cancer
And, enzalutamide improves median overall survival in nonmetastatic, castration-resistant prostate cancer.
